SHR-1210: Clinical Trials

16 trials of SHR-1210, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 unknown, 6 completed, 1 not yet recruiting, 1 recruiting. 16 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 316Unknown 7, Completed 6, Not yet recruiting 1, Recruiting 1, Terminated 1

Follow SHR-1210: new trials by email Literature Review of SHR-1210 trials Research Report on SHR-1210

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Camrelizumab Plus Nab-Paclitaxel and Cisplatin Before Surgery for Locally Advanced Head and Neck Cancer: a Randomized Phase III Trial
Camrelizumab, Nab-paclitaxel, Cisplatin - Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer
Phase 3Not yet recruitingXuekui Liu2122027-01-012026-11-19
Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell
Camrelizumab, Apatinib - Esophageal Cancer
Phase 3UnknownFeng Wang2342021-12-052021-09-20
Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC
Camrelizumab, Placebo, Cisplatin - Non-Small-Cell Lung Cancer
Phase 3CompletedGuangdong Association of Clinical Trials602021-05-282026-05-20
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
camrelizumab, Apatinib Mesylate, Paclitaxel - Gastric Cancer
Phase 3RecruitingJiangsu HengRui Medicine Co., Ltd.5502020-09-212026-01-20
Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
Camrelizumab, Investigator's choice of Chemotherapy - Classical Hodgkin Lymphoma
Phase 3UnknownJiangsu HengRui Medicine Co., Ltd.562020-07-172021-02-08
A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.
Carelizumab, Nab-paclitaxel, Apatinib - Breast Cancer, Triple Negative Breast Cancer
Phase 3TerminatedJiangsu HengRui Medicine Co., Ltd.802020-07-142023-05-06
Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
Camrelizumab, Paclitaxel, Cisplatin - Esophageal Cancer
Phase 3UnknownJiangsu HengRui Medicine Co., Ltd.3962020-06-302021-09-16
A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
SHR-1210, Apatinib, Sorafenib - Locally Advanced or Metastatic and Unresectable HCC
Phase 3CompletedJiangsu HengRui Medicine Co., Ltd.5432019-06-102024-02-06
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.
SHR-1210, FOLFOX4, Placebo - Advanced Hepatocellular Carcinoma
Phase 3UnknownJiangsu HengRui Medicine Co., Ltd.3962019-05-312022-02-10
A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
SHR-1210, Capecitabine, Oxaliplatin - Gastric Cancer, GastroEsophageal Cancer
Phase 3CompletedJiangsu HengRui Medicine Co., Ltd.8852019-03-072025-09-16
Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer
SHR-1210, Placebo, paclitaxel - Advanced Esophageal Cancer
Phase 3CompletedJiangsu HengRui Medicine Co., Ltd.5962018-12-032022-12-07
Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma
Camrelizumab, Placebos, Gemcitabine - Nasopharyngeal Carcinoma
Phase 3UnknownJiangsu HengRui Medicine Co., Ltd.2632018-11-132022-07-01
A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC
SHR-1210, The placebo - Lung Cancer Squamous Cell, Lung Cancer Stage IV
Phase 3UnknownJiangsu HengRui Medicine Co., Ltd.3902018-11-092021-03-15
PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
Camrelizumab - Nasopharyngeal Neoplasms
Phase 3UnknownSun Yat-sen University4502018-07-022024-04-09
A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC
SHR-1210, Carboplatin, Pemetrexed - Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Phase 3CompletedJiangsu HengRui Medicine Co., Ltd.4192017-05-122020-06-09
Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer
camrelizumab, Docetaxel, Irinotecan - Esophageal Carcinoma
Phase 3CompletedJiangsu HengRui Medicine Co., Ltd.4572017-05-052024-01-22

Conditions studied

Esophageal Neoplasms (3)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Lung Neoplasms (2)  ·  Stomach Neoplasms (2)  ·  Breast Neoplasms (1)  ·  Bronchial Neoplasms (1)  ·  Carcinoma, Bronchogenic (1)  ·  Head and Neck Neoplasms (1)  ·  Lung Diseases (1)  ·  Nasopharyngeal Carcinoma (1)  ·  Nasopharyngeal Neoplasms (1)  ·  Neoplasm Metastasis (1)  ·  Neoplasms by Site (1)  ·  Respiratory Tract Diseases (1)  ·  Respiratory Tract Neoplasms (1)

Sponsors

Jiangsu HengRui Medicine Co., Ltd. (12)  ·  Feng Wang (1)  ·  Guangdong Association of Clinical Trials (1)  ·  Sun Yat-sen University (1)  ·  Xuekui Liu (1)

Countries

China (14)  ·  Belgium (1)  ·  Germany (1)  ·  Hong Kong (1)  ·  Italy (1)  ·  Poland (1)  ·  Russia (1)  ·  South Korea (1)  ·  Spain (1)  ·  Taiwan (1)  ·  Turkey (Türkiye) (1)  ·  Ukraine (1)  ·  United States (1)

Top investigators

Caicun Zhou, MD, PhD (1)  ·  Feng Wang (1)  ·  Jianjun Zou, MD, PhD (1)  ·  Jianming Xu, Ph.D (1)  ·  Jun Ma, MD (1)  ·  Li Zhang, MD (1)  ·  Qing Yang (1)  ·  Qing Yang, MD (1)  ·  Ruihua Xu (1)  ·  Shukui Qin, MD (1)  ·  Shukui Qing, MD (1)  ·  Wei Shi, MD (1)  ·  Wu Yi Long, PhD (1)

Results publications

PMID 32416073, PMID 33347829, PMID 34174189, PMID 34519801, PMID 34923163, PMID 34980131, PMID 35936702, PMID 36194670, PMID 36331328, PMID 36646210, PMID 37139963, PMID 37409613, PMID 37499670, PMID 39438442, PMID 39608979, PMID 39929333, PMID 40079940, PMID 41308676, PMID 41609753, PMID 41791006, PMID 41819560